PhaseBio Pharmaceuticals, Inc.
4020 Aerial Center Parkway
Suite 101
Morrisville
North Carolina
27560
United States
Tel: 919-535-8861
Fax: 919-535-8867
Website: http://www.phasebio.com/
39 articles with PhaseBio Pharmaceuticals, Inc.
-
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
10/15/2019
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the first patient has been dosed in a Phase 2b clinical trial of PB2452,
-
Clinical Catch-Up: September 23-27
9/30/2019
It was a moderately busy week for clinical trial news. Here’s a look. -
PhaseBio Receives FDA Breakthrough Therapy Designation and Licenses GLP-1 Analog to ImmunoForge
4/9/2019
PhaseBio Pharmaceuticals, based in Malvern, Penn. and San Diego, announced that its antiplatelet drug PB2452 had received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). -
PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
4/8/2019
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy designation for PB2452, a novel reversal agent for the antiplatelet drug ticagrelor.
-
Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session
3/17/2019
PhaseBio Pharmaceuticals, Inc. announced that results from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet effects without report of drug-related serious adverse events.
-
PhaseBio Appoints Richard A. van den Broek to Board of Directors
3/4/2019
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the appointment of Richard A. van den Broek to its board of directors, effective February 27, 2019.
-
PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiology’s 68th Annual Scientific Session
3/4/2019
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that results from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, have been selected for oral presentation during a featured clinical research session at the American College of Cardiology’s 68th Annual Scientific Session
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
PhaseBio Appoints Edmund P. Harrigan to Board of Directors
12/17/2018
PhaseBio Pharmaceuticals, Inc.(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced the appointment of Edmund P. Harrigan, M.D. to its board of directors, effective December 13, 2018.
-
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
-
A Look Back at October Life Sciences IPOs
10/31/2018
October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month. -
PhaseBio Announces Pricing of Initial Public Offering
10/17/2018
PhaseBio Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 9,200,000 shares of common stock at a price to the public of $5.00 per share, for total gross proceeds of approximately $46.0 million.
-
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
-
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
-
PhaseBio Secures $34 Million in Series D Financing
9/10/2018
Proceeds will advance clinical development of PB2452, a potentially first-in-class reversal agent for patients on ticagrelor, and PB1046, a novel treatment for PAH
-
PhaseBio Announces $15.6M in Funds to Support Clinical Advancement of Orphan Cardiovascular Pipeline
11/29/2017
PhaseBio entered into a $7.5 million term loan facility with Silicon Valley Bank, subject to funding in up to three tranches.
-
PhaseBio Enters Worldwide License Agreement With MedImmune for a Reversal Agent for Ticagrelor
11/28/2017
Ticagrelor is unique among P2Y12 antagonist antiplatelet agents due to its ability to reversibly bind to the receptor, whereas other P2Y12 antagonists bind permanently.
-
PhaseBio Announces Leadership Team Appointments
4/7/2016
-
PhaseBio Receives FDA Orphan Drug Designation For Vasomera (PB1046) For The Treatment Of Cardiomyopathy Associated With Dystrophinopathies
12/1/2015
-
PhaseBio Announces Initiation Of Phase IIa Multiple Ascending Dose Study Of Once-Weekly Basal Insulin PE0139 In Type 2 Diabetes
11/9/2015